Acrivon Therapeutics, Inc.
ACRV
$1.52
-$0.06-3.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -11.08% | -6.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.18% | -13.08% | |||
| Operating Income | -2.18% | 13.08% | |||
| Income Before Tax | -4.12% | 13.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.12% | 13.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.12% | 13.20% | |||
| EBIT | -2.18% | 13.08% | |||
| EBITDA | -2.16% | 13.34% | |||
| EPS Basic | -3.85% | 13.42% | |||
| Normalized Basic EPS | -6.26% | 13.42% | |||
| EPS Diluted | -3.85% | 13.42% | |||
| Normalized Diluted EPS | -6.26% | 13.42% | |||
| Average Basic Shares Outstanding | 0.26% | 0.26% | |||
| Average Diluted Shares Outstanding | 0.26% | 0.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||